Core Insights - Alphatec reported strong financial performance for Q4 and full-year 2025, highlighting continued share gains in spine surgery and improved profitability, marking its first full year of positive free cash flow [4][7][12] Financial Performance - Q4 total revenue reached $213 million, a 20% increase year-over-year, with surgical revenue at $190 million and EOS revenue at $23 million [3][10] - Full-year 2025 revenue was $764 million, up 25% year-over-year, driven by a 22% increase in procedural volume and a 3% rise in average revenue per procedure [10][11] - Adjusted EBITDA for Q4 was $33 million, reflecting a 61% year-over-year increase, with a 16% exit margin [6][9] Growth Drivers - Strategic growth initiatives include leadership in lateral procedures, a controlled rollout of the Valence navigation/robotics platform in 2026, and expanded adoption of EOS/EOS Insight to enhance deformity cases [5][13] - The company signed an exclusive partnership with Theradaptive for a future BMP product, expected to enhance its market position [17] Profitability and Cash Flow - Non-GAAP gross margin for Q4 was 70.5%, up 80 basis points year-over-year, attributed to mix, volume leverage, and improved asset efficiency [8] - The company generated $45 million in cash from operations during 2025, resulting in $3 million of free cash flow, marking a transition to a cash-generating business [12] 2026 Outlook - For 2026, Alphatec projects revenue growth of 17% to approximately $890 million, with surgical revenue expected to be around $805 million [18] - Adjusted EBITDA guidance for 2026 is set at $134 million, implying a margin of about 15%, with expectations for non-GAAP gross margin to approach 71% by year-end [18][19]

Financial Data and Key Metrics Changes - In Q4 2025, total revenue reached $213 million, representing a 20% year-over-year growth, with surgical revenue growing by 21% [3][6] - For the full year 2025, total revenue was $764 million, a $153 million increase year-over-year, equating to a 25% growth [4][16] - Adjusted EBITDA for Q4 was $33 million, reflecting a 61% year-over-year increase, with a margin of 16% [15][22] - Full year Adjusted EBITDA was $93 million, approximately 12% of sales, marking a significant improvement of $63 million year-over-year [17][22] Business Line Data and Key Metrics Changes - Surgical revenue for Q4 was $190 million, while EOS revenue was $23 million, with EOS revenue increasing by 14% year-over-year [6][8] - For the full year, surgical revenue was $687 million, up 26% compared to 2024, driven by a 22% increase in procedural volume [16][17] - EOS revenue for the full year was $77 million, up 15% year-over-year [16] Market Data and Key Metrics Changes - U.S. revenue per case increased by 1.4%, with lateral and cervical cases both up by 6% [7] - Same-store sales in the U.S. grew by 20% year-over-year, indicating strong growth in established territories [8] Company Strategy and Development Direction - The company is focused on creating clinical distinction through proceduralization, particularly in the lateral space, which is seen as a growth engine [24][26] - ATEC aims to expand its market share in spine surgery, particularly in lateral and deformity segments, leveraging its unique procedural ecosystem [26][28] - The company has signed an exclusive distribution partnership with Theradaptive, aiming to introduce a new bone morphogenetic protein (BMP) product to the market [32][33] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the sustainability of top-line growth, driven by increasing surgeon adoption and procedural volume [8][19] - The outlook for 2026 anticipates revenue growth of 17% to approximately $890 million, with Adjusted EBITDA guidance increased to $134 million [19][22] - Management emphasized the importance of building a strong foundation for long-term profitable growth through infrastructure investments and expanding the sales force [33][34] Other Important Information - The company ended Q4 with $161 million in cash and had access to an additional $60 million in undrawn credit, totaling $221 million in available cash [18] - Free cash flow for Q4 was $8 million, marking the first full year of positive free cash flow for the company [18][19] Q&A Session Summary Question: Clarification on Q4 results and 2026 guidance - Analyst inquired about the market reaction to the earnings report and sought confirmation on revenue and EBITDA figures [38] - Management confirmed the accuracy of the reported figures and provided insights on expected seasonal revenue patterns for 2026 [41][42] Question: Attracting sales talent - Analyst asked about the company's ability to attract sales personnel and any notable strengths in specific territories [46] - Management responded that there is strong demand for the company's portfolio, indicating a favorable hiring environment [47]